


Supplementary figure 1. Survival analysis of Chinese and US patients. **A**, Progression free survival (PFS) of patients with or without *PI3K-AKT-mTOR* pathway alteration. **B**, PFS of patients with or without DNA damage repair pathway alteration. *P* value was calculated using log-rank test.



Supplementary figure 2. cfDNA yield between US and Chinese patients. *P* value was calculated using Wilcoxon test.